Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Boardroom

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

- PMLiVE

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

Roche Basel Switzerland

New data reinforces safety profile of Roche’s Hemlibra

Blockbuster haemophilia A treatment presents a strong challenge to rival drugs

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

Impetus Digital Fireside Chat with Jim Lefevere from Roche

Jim Lefevere from Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19. We also touch on the slow but...

Impetus Digital

AstraZeneca AZ

AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

First checkpoint inhibitor to challenge Roche's Tecentriq in this indication

- PMLiVE

UPDATED: Gilead drops remdesivir’s orphan drug designation

Decision comes amid intense public criticism of the regulatory status

Roche Basel Switzerland

FDA approves Roche’s Actemra COVID-19 trial

Plans to initiate trial in early April

- PMLiVE

Gilead halts individual requests for COVID-19 hopeful remdesivir

Will now focus on expanded access programmes and backlog

Roche Basel Switzerland

FDA okays Roche’s COVID-19 diagnostic test

Increases capacity for testing as coronavirus cases grow

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links